WO2018161049A8 - Compositions et procédés pour induire des anticorps anti-vih-1 - Google Patents
Compositions et procédés pour induire des anticorps anti-vih-1 Download PDFInfo
- Publication number
- WO2018161049A8 WO2018161049A8 PCT/US2018/020788 US2018020788W WO2018161049A8 WO 2018161049 A8 WO2018161049 A8 WO 2018161049A8 US 2018020788 W US2018020788 W US 2018020788W WO 2018161049 A8 WO2018161049 A8 WO 2018161049A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- antibodies
- compositions
- inducing hiv
- hiv
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 230000001939 inductive effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- AIDS & HIV (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Selon certains aspects, l'invention concerne des immunogènes du VIH-1, comprenant des enveloppes (CH0848) et des sélections de ces dernières, et des procédés d'immunisation en essaim à l'aide de combinaisons d'enveloppes de VIH-1.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18760878.1A EP3589315A4 (fr) | 2017-03-03 | 2018-03-02 | Compositions et procédés pour induire des anticorps anti-vih-1 |
CA3055204A CA3055204A1 (fr) | 2017-03-03 | 2018-03-02 | Compositions et procedes pour induire des anticorps anti-vih-1 |
US16/489,245 US11318197B2 (en) | 2016-03-03 | 2018-03-02 | Compositions and methods for inducing HIV-1 antibodies |
US16/977,408 US20210009640A1 (en) | 2018-03-02 | 2019-03-01 | Compositions comprising hiv envelopes to induce hiv-1 antibodies |
CA3092925A CA3092925A1 (fr) | 2018-03-02 | 2019-03-01 | Compositions comprenant des enveloppes de vih pour induire des anticorps anti-vih -1 |
PCT/US2019/020436 WO2019169356A1 (fr) | 2018-03-02 | 2019-03-01 | Compositions comprenant des enveloppes de vih pour induire des anticorps anti-vih -1 |
EP19761696.4A EP3758734A4 (fr) | 2018-03-02 | 2019-03-01 | Compositions comprenant des enveloppes de vih pour induire des anticorps anti-vih -1 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2017/020823 WO2017152146A2 (fr) | 2016-03-03 | 2017-03-03 | Compositions et procédés pour induire des anticorps du vih-1 |
USPCT/US2017/020823 | 2017-03-03 | ||
US201862624620P | 2018-01-31 | 2018-01-31 | |
US62/624,620 | 2018-01-31 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/977,408 Continuation US20210009640A1 (en) | 2018-03-02 | 2019-03-01 | Compositions comprising hiv envelopes to induce hiv-1 antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2018161049A1 WO2018161049A1 (fr) | 2018-09-07 |
WO2018161049A8 true WO2018161049A8 (fr) | 2018-10-04 |
Family
ID=63371208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2018/020788 WO2018161049A1 (fr) | 2016-03-03 | 2018-03-02 | Compositions et procédés pour induire des anticorps anti-vih-1 |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3589315A4 (fr) |
CA (1) | CA3055204A1 (fr) |
WO (1) | WO2018161049A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3423472A4 (fr) | 2016-03-01 | 2019-12-25 | Duke University | Compositions comprenant des enveloppes de vih pour induire des anticorps de lignée ch235 |
US11318197B2 (en) | 2016-03-03 | 2022-05-03 | Duke University | Compositions and methods for inducing HIV-1 antibodies |
WO2017152146A2 (fr) | 2016-03-03 | 2017-09-08 | Duke University | Compositions et procédés pour induire des anticorps du vih-1 |
CA3039089A1 (fr) | 2016-10-03 | 2018-04-12 | Duke University | Procedes d'identification d'immunogenes par ciblage de mutations improbables |
WO2019169356A1 (fr) * | 2018-03-02 | 2019-09-06 | Duke University | Compositions comprenant des enveloppes de vih pour induire des anticorps anti-vih -1 |
CA3115232A1 (fr) * | 2018-10-01 | 2020-04-09 | Duke University | Compositions comprenant des enveloppes de vih pour induire des anticorps contre le vih-1 |
KR20210124205A (ko) * | 2018-12-04 | 2021-10-14 | 더 락커펠러 유니버시티 | Hiv 백신 면역원 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014043386A1 (fr) * | 2012-09-12 | 2014-03-20 | Duke University | Anticorps du lignage clonal |
WO2015127108A1 (fr) | 2014-02-19 | 2015-08-27 | Duke University | Enveloppes du vih -1 trimères des compositions et leurs utilisations |
CA2944068A1 (fr) * | 2014-03-31 | 2015-10-08 | Duke University | Compositions comprenant des enveloppes de ch848, et leurs utilisations |
US10400015B2 (en) | 2014-09-04 | 2019-09-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant HIV-1 envelope proteins and their use |
-
2018
- 2018-03-02 CA CA3055204A patent/CA3055204A1/fr active Pending
- 2018-03-02 WO PCT/US2018/020788 patent/WO2018161049A1/fr unknown
- 2018-03-02 EP EP18760878.1A patent/EP3589315A4/fr active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2018161049A1 (fr) | 2018-09-07 |
CA3055204A1 (fr) | 2018-09-07 |
EP3589315A1 (fr) | 2020-01-08 |
EP3589315A4 (fr) | 2021-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018161049A8 (fr) | Compositions et procédés pour induire des anticorps anti-vih-1 | |
WO2017152146A3 (fr) | Compositions et procédés pour induire des anticorps du vih-1 | |
PH12018502601A1 (en) | Anti-b7-h3 antibodies and antibody drug conjugates | |
MX2023014120A (es) | Formulaciones de anticuerpos inhibidores de masp-2 altamente concentradas de baja viscosidad, kits, y metodos. | |
MX2019007020A (es) | Anticuerpos il-11. | |
AU2016264323A8 (en) | Compositions and methods for TCR reprogramming using fusion proteins | |
MX2018015853A (es) | Anticuerpos multiespecificos frente a los grupos de diferenciacion 40 y 137 (cd40 y cd137). | |
MX2019006043A (es) | Proteína de unión de antígeno prostático específico de membrana. | |
PH12018501043A1 (en) | Site specific her2 antibody drug conjugates | |
PH12018501336A1 (en) | Dendritic cell composition | |
MX2018001497A (es) | Proteinas de fusion de factor ix y metodos para producirlas y usarlas. | |
WO2017151801A8 (fr) | Compositions comprenant des enveloppes de vih pour induire des anticorps de lignée ch235 | |
MX2018015277A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. | |
MX2018015285A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. | |
MX2018015272A (es) | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. | |
PH12020551716A1 (en) | Anti-ror antibody constructs | |
MX2021005373A (es) | Variantes de proteinas de union al factor h y metodos de uso de estas. | |
PH12019501872A1 (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
MX2018015268A (es) | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. | |
MX2018015274A (es) | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. | |
MX2018015280A (es) | Conjugados de anticuerpo y farmaco anti-egfr. | |
MX2018015284A (es) | Conjugados de anticuerpo anti-egfr y fármaco. | |
MX2021003180A (es) | Métodos y kits para preparar sangre entera con inactivación de patógenos. | |
MX2019013124A (es) | Proteinas de fusion de inhibidor de tripsina urinaria (uti). | |
WO2018138681A9 (fr) | Anticorps spécifiques de l'hémagglutinine et leurs utilisations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18760878 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3055204 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018760878 Country of ref document: EP Effective date: 20191004 |